Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on December 13, 2012, regarding events occurring on December 12, 2012. The filing discloses the entry into material definitive agreements for a registered direct offering of common stock and an amendment to an existing sales agreement. Note: The request metadata referenced "Madrigal Pharmaceuticals," but the source text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics and Transaction Details
- Offering Size: 7,000,000 shares of common stock.
- Offering Price: $8.60 per share (consolidated closing bid price on December 12, 2012).
- Gross Proceeds: Approximately $60.2 million (7,000,000 shares x $8.60).
- Net Proceeds: Approximately $59.8 million after estimated expenses.
- Closing Date: Expected on or about December 18, 2012.
- Sales Method: Direct sale to investors without a placement agent, underwriter, broker, or dealer.
Material Changes and Agreements
Common Stock Purchase Agreements
The Company entered into purchase agreements for the registered direct offering. Significant participation from Board members and affiliates includes:
- Bruce Kovner (Director/Largest Stockholder): Agreed to purchase 2,325,581 shares. Post-offering beneficial ownership will be approximately 29.8%.
- Keith R. Gollust (Director): Affiliated entities agreed to purchase 250,000 shares. Post-offering beneficial ownership will be approximately 4.6%.
- Robert N. Wilson (Director): Agreed to purchase 58,140 shares. Post-offering beneficial ownership will be approximately 1.1%.
- Donald W. Kufe (Director): Agreed to purchase 5,814 shares. Post-offering beneficial ownership will remain less than 1%.
- Safi R. Bahcall (CEO/President/Director): Agreed to purchase 10,000 shares. Post-offering beneficial ownership will be approximately 4.3%.
Amendment to At the Market Issuance Sales Agreement
The Company amended its May 2, 2012, Sales Agreement with MLV & Co. LLC. The aggregate offering price available for sale under this agreement was reduced from $35.0 million to $28.0 million.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future operational performance. The document focuses strictly on the mechanics of the capital raise. The filing includes standard legal disclaimers noting that representations and warranties in the purchase agreements were made solely for the benefit of the contracting parties and may not reflect facts applicable to general investors.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received (expected ~$59.8 million).
- Confirm the updated share count and dilution impact on existing shareholders post-closing.
- Review the specific terms of the amended At the Market Sales Agreement (Exhibit 10.2) to understand remaining capacity for future sales.
- Check subsequent filings for the use of proceeds and any changes in the Company's liquidity position.